Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Vaxcyte (PCVX) Invested Capital (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Invested Capital data on record, last reported at $3.0 billion in Q1 2026.

  • On a quarterly basis, Invested Capital fell 6.38% to $3.0 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $3.0 billion, a 6.38% decrease, with the full-year FY2025 number at $2.7 billion, down 18.76% from a year prior.
  • Invested Capital reached $3.0 billion in Q1 2026 per PCVX's latest filing, up from $2.7 billion in the prior quarter.
  • Over the last five years, Invested Capital for PCVX hit a ceiling of $3.4 billion in Q3 2024 and a floor of $359.3 million in Q3 2022.
  • A 5-year average of $1.9 billion and a median of $2.0 billion in 2024 define the central range for Invested Capital.
  • Peak YoY movement for Invested Capital: surged 291.1% in 2023, then fell 18.76% in 2025.
  • Tracing PCVX's Invested Capital over 5 years: stood at $953.6 million in 2022, then skyrocketed by 30.08% to $1.2 billion in 2023, then soared by 166.5% to $3.3 billion in 2024, then dropped by 18.76% to $2.7 billion in 2025, then grew by 11.56% to $3.0 billion in 2026.
  • Business Quant data shows Invested Capital for PCVX at $3.0 billion in Q1 2026, $2.7 billion in Q4 2025, and $2.9 billion in Q3 2025.